Italia markets closed

Abeona Therapeutics Inc. (0H7R.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,1940-0,0040 (-2,02%)
Alla chiusura: 06:10PM BST
Schermo intero
Chiusura precedente0,1980
Aperto0,1902
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno0,1902 - 0,1940
Intervallo di 52 settimane0,1902 - 0,1940
Volume6.500
Media VolumeN/D
Capitalizzazione5,42M
Beta (5 anni mensile)1,50
Rapporto PE (ttm)N/D
EPS (ttm)-0,8080
Prossima data utili27 lug 2022 - 01 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Abeona Therapeutics to Present at the Jefferies Healthcare Conference

    NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 3:30 p.m. EDT. A live webcast of the presentation will be available on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events. The webcast will be archived for 3

  • GlobeNewswire

    Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule

    NEW YORK and CLEVELAND, May 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has been granted an additional 180-day period from Nasdaq’s Listing Qualification Department, through November 14, 2022, to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company's common stock continues to trade on the Nasdaq Capital Market und

  • GlobeNewswire

    Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics

    ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy (ASGCT) today NOVATO, Calif. and NEW YORK and CLEVELAND, May 17, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome